-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Jefferies Financial Group Comments on RVL Pharmaceuticals Plc's FY2025 Earnings (NASDAQ:RVLP)
Jefferies Financial Group Comments on RVL Pharmaceuticals Plc's FY2025 Earnings (NASDAQ:RVLP)
RVL Pharmaceuticals plc (NASDAQ:RVLP – Get Rating) – Jefferies Financial Group decreased their FY2025 earnings per share (EPS) estimates for shares of RVL Pharmaceuticals in a research note issued to investors on Monday, January 9th. Jefferies Financial Group analyst G. Santangelo now forecasts that the company will post earnings per share of $0.00 for the year, down from their previous forecast of $0.01. Jefferies Financial Group currently has a "Hold" rating and a $2.50 target price on the stock. The consensus estimate for RVL Pharmaceuticals' current full-year earnings is ($0.66) per share. Jefferies Financial Group also issued estimates for RVL Pharmaceuticals' FY2026 earnings at $0.13 EPS.
Get RVL Pharmaceuticals alerts:RVL Pharmaceuticals (NASDAQ:RVLP – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.03. The firm had revenue of $10.02 million during the quarter, compared to analysts' expectations of $10.05 million. RVL Pharmaceuticals had a negative return on equity of 92.27% and a negative net margin of 124.13%.
Separately, Barclays dropped their price objective on RVL Pharmaceuticals from $4.00 to $3.00 and set an "overweight" rating on the stock in a research note on Tuesday, October 25th.RVL Pharmaceuticals Trading Up 5.9 %
RVL Pharmaceuticals stock opened at $1.26 on Thursday. The company has a debt-to-equity ratio of 0.82, a quick ratio of 3.27 and a current ratio of 3.30. The business's 50-day simple moving average is $1.34 and its 200-day simple moving average is $1.72. The firm has a market capitalization of $124.93 million, a PE ratio of -2.03 and a beta of 1.17. RVL Pharmaceuticals has a 52 week low of $0.99 and a 52 week high of $2.99.
Institutional Investors Weigh In On RVL Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP raised its position in RVL Pharmaceuticals by 18.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 86,361 shares of the company's stock worth $182,000 after purchasing an additional 13,738 shares during the last quarter. Tower Research Capital LLC TRC bought a new position in RVL Pharmaceuticals in the 3rd quarter worth approximately $32,000. IPG Investment Advisors LLC bought a new position in RVL Pharmaceuticals in the 3rd quarter worth approximately $37,000. Virtu Financial LLC bought a new position in RVL Pharmaceuticals in the 3rd quarter worth approximately $48,000. Finally, Prudential Financial Inc. bought a new position in RVL Pharmaceuticals in the 2nd quarter worth approximately $34,000. 62.91% of the stock is owned by institutional investors and hedge funds.
RVL Pharmaceuticals Company Profile
(Get Rating)
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults.
Featured Stories
- Get a free copy of the StockNews.com research report on RVL Pharmaceuticals (RVLP)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for RVL Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RVL Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
RVL制药公司(纳斯达克代码:RVLP-GET Rating)-杰富瑞金融集团在1月9日星期一发布给投资者的一份研究报告中下调了对RVL制药公司股票2025财年每股收益(EPS)的预期。杰富瑞金融集团分析师G.Santangelo现在预测,该公司今年的每股收益将为0.00美元,低于此前预测的0.01美元。杰富瑞金融集团目前对该股的评级为持有,目标价为2.50美元。对RVL PharmPharmticals目前全年收益的普遍估计为每股0.66美元。杰富瑞金融集团还发布了对RVL制药公司2026财年每股收益的估计为0.13美元。
到达RVL制药公司警报:RVL制药(纳斯达克:RVLP-GET Rating)最近一次发布季度收益数据是在11月10日(星期四)。该公司公布了该季度每股收益(EPS)(0.16美元),比分析师普遍预期的(0.19美元)高出0.03美元。该公司本季度营收为1,002万美元,高于分析师预期的1,005万美元。RVL制药公司的净资产回报率为负92.27%,净利润率为负124.13%。
另外,巴克莱将RVL PharmPharmticals的目标价从4.00美元下调至3.00美元,并在10月25日(星期二)的一份研究报告中对该股设定了“增持”评级。RVL制药公司股价上涨5.9%
RVL PharmPharmticals股票周四开盘报1.26美元。该公司的负债权益比率为0.82,速动比率为3.27,流动比率为3.30。该业务的50日简单移动均线切入位在1.34美元,200日简单移动均线切入位在1.72美元。该公司市值为1.2493亿美元,市盈率为-2.03,贝塔系数为1.17。RVL PharmPharmticals的52周低点为0.99美元,52周高点为2.99美元。
机构投资者买入RVL制药公司
机构投资者最近增持或减持了该股。Dimension Fund Advisors LP在第三季度将其在RVL PharmPharmticals的头寸提高了18.9%。Dimension Fund Advisors LP在上个季度额外购买了13,738股后,现在拥有86,361股该公司股票,价值182,000美元。Tower Research Capital LLC TRC在第三季度购买了RVL制药公司的一个新头寸,价值约3.2万美元。IPG Investment Advisors LLC在第三季度购买了RVL制药公司的新头寸,价值约3.7万美元。Virtu Financial LLC在第三季度购买了RVL制药公司的一个新头寸,价值约4.8万美元。最后,保诚金融公司在第二季度购买了RVL制药公司的新头寸,价值约3.4万美元。62.91%的股票由机构投资者和对冲基金持有。
RVL制药公司简介
(获取评级)
RVL PharmPharmticals plc是一家专业制药公司,专注于药品的开发和商业化,目标市场是美国、阿根廷和匈牙利眼科和医学美学治疗领域服务不足的患者群体。该公司正在商业化Upneq(RVL-1201),一种盐酸羟甲唑啉眼液,用于治疗成人获得性眼睑下垂。
专题报道
- 免费获取StockNews.com关于RVL制药的研究报告(RVLP)
- Bloom Energy在升级后启动,值得冒这个险吗?
- 好时为什么是一只甜蜜的衰退股票
- 亚马逊股票是否会在2023年为投资者提供服务?
- 分析师将货运情绪转回远期
- 各机构预订波音航班
接受《RVL制药日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对RVL制药和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧